The NxStage Medical Inc. (NXTM) CEO Sold $180,075.00 in Stock

The NxStage Medical Inc. (NXTM) CEO Sold $180,075.00 in Stock

NxStage Medical Inc. (NASDAQ:NXTM) CEO Jeffrey H. Burbank sold 7,500 shares of the business’s stock in a transaction dated Wednesday, November 23rd. The stock was sold at an average price of $24.01, for a total transaction of $180,075.00. Following the transaction, the chief executive officer now owns 897,616 shares in the company, valued at approximately $21,551,760.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

NxStage Medical Inc. (NASDAQ:NXTM) opened at 26.03 on Monday. NxStage Medical Inc. has a 52-week low of $13.49 and a 52-week high of $26.83. The firm’s market capitalization is $1.69 billion. The firm has a 50-day moving average of $24.29 and a 200-day moving average of $22.57.

Several research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating in a report on Wednesday, August 10th. Canaccord Genuity restated a “buy” rating and set a $28.00 price objective on shares of NxStage Medical in a report on Thursday, November 3rd. BTIG Research restated a “buy” rating and set a $29.00 price objective on shares of NxStage Medical in a report on Sunday, August 7th. Jefferies Group boosted their price objective on shares of NxStage Medical from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Friday, August 5th. Finally, Northland Securities set a $25.00 price objective on shares of NxStage Medical and gave the stock a “buy” rating in a report on Thursday, September 15th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $25.67.

A number of hedge funds have recently made changes to their positions in NXTM. GSA Capital Partners LLP boosted its stake in shares of NxStage Medical by 98.4% in the second quarter. GSA Capital Partners LLP now owns 40,426 shares of the medical device company’s stock worth $876,000 after buying an additional 20,046 shares in the last quarter. Granite Point Capital Management L.P. bought a new position in shares of NxStage Medical during the second quarter valued at $1,451,000. State Board of Administration of Florida Retirement System raised its position in shares of NxStage Medical by 1.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 49,876 shares of the medical device company’s stock valued at $1,081,000 after buying an additional 640 shares during the last quarter. California Public Employees Retirement System raised its position in shares of NxStage Medical by 7.6% in the second quarter. California Public Employees Retirement System now owns 128,800 shares of the medical device company’s stock valued at $2,792,000 after buying an additional 9,100 shares during the last quarter. Finally, Swiss National Bank raised its position in shares of NxStage Medical by 15.3% in the second quarter. Swiss National Bank now owns 106,800 shares of the medical device company’s stock valued at $2,315,000 after buying an additional 14,200 shares during the last quarter.

About NxStage Medical

Related posts

Leave a Comment